The Programme Faculty Panel is comprised of representatives from:

Lean Life Science, Cancer Research UK, MCRC, 4 global pharma companies, plus CRO partners.

Delivered by:

a unique team of seasoned oncology R&D professionals, commercial, and investment specialists.

ODP2 consists of three parts:

Part One

24 January 2023

Is an immersive one-day masterclass.

Part two

7 - 9 March 2023

Is a three-day deep dive into the highly successful Lean Life Science approach to developing oncology assets and securing investment, engaging directly with pharma and CRO experts.

Part Three

June - October 2023

By application, will see selected participants work closely with the partners to create and validate the integrated plans necessary to ensure successful development and attract potential funding.



 An intensive 5-month programme, supporting innovators or funders to become match fit to tell a compelling value story to investors.

ODP2 Part 3: DEVELOP will cover:

Gap analysis

  • Validating line of sight with industry, academia and/or clinicians
  • Exploring & validating commercial strategy & business model
  • Engaging with CRO delivery partners
  • Milestone setting

Project planning & costing

  • Finance modelling and business valuation
  • Strategic plans: Regulatory, Safety, Pre-clin/clin, IP, Valuation,
  • Pitch development and practice



7 - 9 March 2023

7th March

Voice of the customer:

What data do I need to see when considering in-licensing innovation?

  • Talks from Pharma (Johnson & Johnson, Roche)

Anna Williamson

Executive Director, Global and UK Pharma Partnering, Roche

Richard Ward

Group Systems Director, AstraZeneca

Andrew Crockford

Director Early Innovation Partnering – Oncology, Johnson & Johnson


Hints and tips on how to access the UK’s publicly funded R&D delivery ecosystem

  • A panel discussion with key stakeholders including universities, NHS, translational centres

Rahul Kapoor

Director of Health Tech, CPI

Helen Cole

Industry Partnerships Manager, NHSA

Lee Dunham

Cell & Gene Therapy Catapult

Sajni Haria

Business Development Manager, NIHR

Daniel Zamora

Health Innovation Manchester

Hints and tips on how to engage with Contract Research Organisations

  • A biotech perspective

Nigel Brooks

Coach and Advisor, Lean Life Science


What it takes to develop an oncology innovation into a product

  • Diagnostics, medical devices, digital/computational products

Jane Theaker

Chief Executive Officer, PbD Biotech

Paul Riley

Pharmaceutical & Life Sciences Consultant, Glasshouse Health

Critical external considerations for developing an oncology innovation into a product

  • Intellectual property, regulatory, safety/tox considerations)

Lucy Padget

Patent Attorney & Partner, Alembia Intellectual Property

Bob Clay

Managing Director, Highbury Regulatory Science Limited

8th March

Case study of success

Talk from an academic on their entrepreneurial journey

Helen Philippou

Founder Director of LUNAC Therapeutics

Start with the end in mind

The importance of internal strategic planning

David Cook

Chief Scientific Officer, Blueberry Therapeutics

Nigel Brooks

Coach and Advisor, Lean Life Science

Voice of the customer

What do I need to see in a pitch to consider an innovation “investment ready”?

  • Talk from a Venture Capital investor

Genghis Lloyd-Harris

Venture Partner, Abingworth


  • Introduction to lean innovation concepts, language & tools
  • Opportunity to practice application of tools & use them to prepare for meet expert sessions on Day 3

Ned Wakeman

Founder & CEO, Lean Life Science

9th March

Meet the experts

  • Virtual partnering platform to secure 1:1 meetings with pharma companies, delivery partners (CROs) & Experts in Residence

PART 1 masterclass


24 January 2023

overview of odp2

case studies of success

  • PBD Biotech, Oncodrug, ImmTune Therapies

what good looks like

Investor Perspective

  • Abingworth
    Genghis Lloyd-Harris, Partner
  • SVLS
    Alex Badamchi-Zadeh, Sr Investment Associate (CRUK Seed Fund)
  • OSE
    Claire Brown, Partner


Pharma Perspective

  • AstraZeneca
    Shaun Grady, Snr VP Bus Dev
  • GSK
    Jeremy Griggs, Senior Director Bus Dev
  • Novartis
    Carla Bauer, Novartis NIBR BD&L S&E / Transactions